Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Sulfamethoxazole and Trimethoprim Tablets

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Ongoing Particulate / foreign matter Amneal Pharmaceuticals, LLC NDC 65162-272-10 D-0615-2025
Class II · Moderate risk

Lisdexamfetamine Dimesylate Capsules

Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg.

Terminated Labeling / mix-up Lannett Company Inc. NDC 0527-4664-37 D-0599-2025
Class II · Moderate risk

Theophylline extended-release tablets 400mg

Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution criteria.

Ongoing Dissolution failure Glenmark Pharmaceuticals Inc., USA NDC 68462-380-01 D-0583-2025
Class II · Moderate risk

Carvedilol Tablets

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-165-05 D-0579-2025
Class II · Moderate risk

Carvedilol Tablets

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-164-05 D-0578-2025
Class II · Moderate risk

Carvedilol Tablets

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-162-05 D-0577-2025
Class II · Moderate risk

Carvedilol Tablets

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA D-0588-2025
Class II · Moderate risk

Carvedilol Tablets

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-164-05 D-0587-2025
Class II · Moderate risk

Metoprolol Tartrate Tablets

CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.

Ongoing Nitrosamine impurity Westminster Pharmaceuticals LLC NDC 69367-355-10 D-0582-2025
Class II · Moderate risk

Metoprolol Tartrate Tablets

CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.

Ongoing Nitrosamine impurity Westminster Pharmaceuticals LLC NDC 69367-354-10 D-0581-2025
Class II · Moderate risk

Enoxaparin Sodium Injection

Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Ongoing Labeling / mix-up Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class III · Low risk

Sensodyne PRONAMEL

Labeling: Label Mix-up: The outer carton is labelled Fresh Mint. The tube is labelled Cool Mint/Whitening. The toothpaste inside the tube is Fresh Mint as indicated on the outer carton

Ongoing Labeling / mix-up Haleon US Holdings LLC D-0592-2025
Class II · Moderate risk

Recombinate

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. D-0573-2025
Class II · Moderate risk

Xolair (omalizumab injection)

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. NDC 50242-214-55 D-0572-2025

Recalls by year